Dreno C, Gicquel T, Harry M, Tribut O, Aubin F, Brandhonneur N, Dollo G
Pôle pharmaceutique, CHU Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France.
Laboratoire de toxicologie biologique et médico-légale, CHU Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France.
Ann Pharm Fr. 2015 Jan;73(1):31-6. doi: 10.1016/j.pharma.2014.06.006. Epub 2014 Jul 14.
We present formulation and stability evaluation of a 2% (w/v) phenylephrine hydrochloride biocompatible eye drop solution, routinely prepared in hospital pharmacy under aseptic conditions, for retinal examination of neonates and premature infants.
Eye drop solution was formulated by dissolution of phenylephrine hydrochloride and disodium hydrogen phosphate as buffering agent in sterile water for injection and sodium chloride for injection as isotonic agent. The previous solution was sterile filtered through under aseptic conditions, in an iso class 5 air quality clean room under horizontal laminar airflow hood. Physical stability (visual inspection, osmolality measurements), chemical stability (pH measurement, phenylephrine assay by liquid chromatography coupled with an ultra-high resolution and accurate mass) and sterility evaluation of phenylephrine eye drop solution stored at ambient temperature were studied during 60 days.
The formulated eye drop solution had a pH of 6.90±0.05 and an osmolality of 285±2 mOsm/kg. Throughout the 60 days study the solutions remained clear without any precipitation or color modification, sterility was maintained, pH and osmolality were not significantly modified and no significant loss of product was detected using liquid chromatography coupled with an ultra-high resolution and accurate mass instrument suggesting the lack of degradation.
These results indicate that 2% phenylephrine hydrochloride eye drop solutions were physically, chemically and microbiologically stable for at least 60 days when stored in type I amber glass vials at room temperature, allowing the compounding of higher batch sizes.
我们展示了一种2%(w/v)盐酸去氧肾上腺素生物相容性滴眼液的配方及稳定性评估,该滴眼液通常在医院药房无菌条件下制备,用于新生儿和早产儿的视网膜检查。
通过将盐酸去氧肾上腺素和作为缓冲剂的磷酸氢二钠溶解于注射用无菌水中,并加入作为等渗剂的注射用氯化钠来配制滴眼液。将先前的溶液在无菌条件下,于ISO 5级空气质量洁净室内的水平层流通风橱中进行无菌过滤。研究了在室温下储存60天期间,盐酸去氧肾上腺素滴眼液的物理稳定性(外观检查、渗透压测量)、化学稳定性(pH测量、通过超高效液相色谱和精确质量分析进行的去氧肾上腺素含量测定)以及无菌性评估。
所配制的滴眼液pH值为6.90±0.05,渗透压为285±2 mOsm/kg。在整个60天的研究过程中,溶液保持澄清,无任何沉淀或颜色变化,保持无菌,pH值和渗透压无显著变化,并且使用超高效液相色谱和精确质量仪器未检测到产品有显著损失,表明未发生降解。
这些结果表明,2%盐酸去氧肾上腺素滴眼液在室温下储存在I型琥珀玻璃瓶中时,在物理、化学和微生物学方面至少60天是稳定的,从而可以配制更大批量的产品。